The VHL tumor suppressor in development and disease: Functional studies in mice by conditional gene targeting
- 1 August 2005
- journal article
- review article
- Published by Elsevier in Seminars in Cell & Developmental Biology
- Vol. 16 (4-5) , 564-574
Abstract
No abstract availableKeywords
This publication has 122 references indexed in Scilit:
- Inactivation of the Arylhydrocarbon Receptor Nuclear Translocator (Arnt) Suppresses von Hippel-Lindau Disease-Associated Vascular Tumors in MiceMolecular and Cellular Biology, 2005
- Differentiating the functional role of hypoxia‐inducible factor (HIF)‐1α and HIF‐2α (EPAS‐1) by the use of RNA interference: erythropoietin is a HIF‐2α target gene in Hep3B and Kelly cellsThe FASEB Journal, 2004
- Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma CellsJournal of Biological Chemistry, 2003
- Disruption of oxygen homeostasis underlies congenital Chuvash polycythemiaNature Genetics, 2002
- Structural basis for the recognition of hydroxyproline in HIF-1α by pVHLNature, 2002
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- Independent function of two destruction domains in hypoxia‐inducible factor‐α chains activated by prolyl hydroxylationThe EMBO Journal, 2001
- Perivenous expression of the mRNA of the three hypoxia-inducible factor α-subunits, HIF1α, HIF2α and HIF3α, in rat liverBiochemical Journal, 2001
- Mechanism of regulation of the hypoxia‐inducible factor‐1α by the von Hippel‐Lindau tumor suppressor proteinThe EMBO Journal, 2000
- Erythropoietin stimulates proliferation of human renal carcinoma cellsKidney International, 2000